

11-5-02

642
Box 509

NOV 01 2002 Docket No: R-237.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: SCHEIFLINGER, et al


Group Art Unit: 1644

Application No: 09/661,992

Examiner: DeCloux, A.

Filed: September 14, 2000

For: FACTOR IX/FACTOR IXa ACTIVATING
ANTIBODIES AND ANTIBODY DERIVATIVES



Assistant Commissioner of Patents
U.S. Patent and Trademark Office
Box Sequence
P. O. Box 2327
Arlington, VA 22202

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

In response to the Notice To Comply dated July 1, 2002, enclosed are:

- Preliminary Amendment
- Diskette containing sequence listings
- Paper copy of sequence listings
- Copy of Notice to Comply
- Request for three-months extension of time

Date: November 1, 2002

Respectfully submitted,


Michael F. Fedrick

Michael F. Fedrick, Reg. No. 36,799
Baxter Healthcare Corporation
Post Office Box 15210
Irvine, California 92623-5210
Telephone: (818) 550-4569
Facsimile: (818) 550-4567

CERTIFICATE OF MAILING

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail No. EL861608193US in an envelope addressed to, Assistant Commissioner for Patents, U. S. Patent and Trademark Office, Box Sequence, PO Box 2327, Arlington, VA 22202 on November 1, 2002.

By: *Diane Branham*
Diane Branham



(<<http://www.uspto.gov/ebs/efs/downloads/documents.htm>>, EFS
Submission User Manual - ePAVE)

2. Mailed to:
U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:
U. S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at:
2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
Arlington, Virginia 22202

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy DeCloux whose telephone number is (703) 306-5821. The examiner can normally be reached Monday through Friday from 9:00 am to 6:00 pm. Or a message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Amy DeCloux, Ph.D.
Patent Examiner
Group 1640
Technology Center 1600
July 1, 2002

Amy DeCloux
7-1-02.

NOV 01 2002

Application No.: 09/661,992

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2 This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Claim 7 recites **peptides not identified by SEQ ID NO: tags.**

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE